Tibor Kovacsovics

6.4k total citations
123 papers, 3.7k citations indexed

About

Tibor Kovacsovics is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Tibor Kovacsovics has authored 123 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 97 papers in Hematology, 51 papers in Molecular Biology and 34 papers in Genetics. Recurrent topics in Tibor Kovacsovics's work include Acute Myeloid Leukemia Research (63 papers), Multiple Myeloma Research and Treatments (26 papers) and Acute Lymphoblastic Leukemia research (25 papers). Tibor Kovacsovics is often cited by papers focused on Acute Myeloid Leukemia Research (63 papers), Multiple Myeloma Research and Treatments (26 papers) and Acute Lymphoblastic Leukemia research (25 papers). Tibor Kovacsovics collaborates with scholars based in United States, Switzerland and France. Tibor Kovacsovics's co-authors include John H. Hartwig, Lewis C. Cantley, Jeffrey E. Lancet, Daniel J. DeAngelo, Lloyd E. Damon, Anjali S. Advani, Christilla Bachelot‐Loza, Norbert Vey, Xavier Thomas and André Delannoy and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Tibor Kovacsovics

119 papers receiving 3.7k citations

Peers

Countries citing papers authored by Tibor Kovacsovics

Since Specialization

Citations

This map shows the geographic impact of Tibor Kovacsovics's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tibor Kovacsovics with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tibor Kovacsovics more than expected).

Fields of papers citing papers by Tibor Kovacsovics

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tibor Kovacsovics. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tibor Kovacsovics. The network helps show where Tibor Kovacsovics may publish in the future.

Co-authorship network of co-authors of Tibor Kovacsovics

This figure shows the co-authorship network connecting the top 25 collaborators of Tibor Kovacsovics. A scholar is included among the top collaborators of Tibor Kovacsovics based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tibor Kovacsovics. Tibor Kovacsovics is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The genetic landscape of germlineDDX41variants predisposing to myeloid neoplasms 2022 ·Blood ·Peng Li, (unknown), Margaret S. Williams, Thomas A. White, Wei Xie, Wei Cui, Deniz Peker, (unknown), Christian A. Kunder, Huan‐You Wang, Sarah Murray, (unknown), Tibor Kovacsovics, Jay Patel	43
2	A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes 2022 ·Annals of Hematology ·Mikkael A. Sekeres, Michael Schuster, Magalie Joris, Jürgen Krauter, Johan Maertens, Dimitri Breems, Emmanuel Gyan, Tibor Kovacsovics, Amit Verma, Paresh Vyas, Eunice S. Wang, Keith A. Ching, Thomas O’Brien, Corrado Gallo Stampino, Weidong Wendy, Arthur J. Kudla, Geoffrey Chan, Amer M. Zeidan	11
3	AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome 2021 ·Leukemia ·Peng Li, Thomas A. White, Wei Xie, Wei Cui, Deniz Peker, (unknown), Huan‐You Wang, (unknown), (unknown), Margaret S. Williams, Tibor Kovacsovics, Jay Patel	36
4	Utility of Biomarkers in Cardiac Amyloidosis 2020 ·JACC Heart Failure ·(unknown), (unknown), (unknown), Tibor Kovacsovics, José Nativi-Nicolau	26
5	Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective 2018 ·Leukemia ·Hein Than, 義行高橋, Xiaomeng Huang, Dongqing Yan, Jamshid S. Khorashad, Anthony D. Pomicter, Tibor Kovacsovics, Gábor Marth, Thomas O’Hare, Michael W. Deininger	5
6	Comparison of Proteasome Inhibition Activity between Carfilzomib and Bortezomib in the Phase 3 Endeavor Study 2017 ·Blood ·Heinz Ludwig, Andrew Spencer, Tibor Kovacsovics, Nashat Gabrail, Leonard Minuk, Amy Kimball, Robert J. Pelham, Ying Ou, Robert Z. Orlowski	4
7	FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia 2016 ·Cancer Research ·Elie Traer, Jacqueline Martinez, Nathalie Javidi‐Sharifi, Anupriya Agarwal, Jennifer Dunlap, Isabel A. English, Tibor Kovacsovics, Jeffrey Tyner, Melissa H. Wong, Brian Druker	96
8	Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Patients with Hematologic Malignancies Using Busulfan, Fludarabine, and Total Body Irradiation Conditioning Is Effective in an Elderly and Infirm Population 2014 ·Biology of Blood and Marrow Transplantation ·Jonathan E. Brammer, (unknown), James Gajewski, Peter Curtin, Brandon Hayes‐Lattin, Tibor Kovacsovics, José F. Leis, Gabrielle Meyers, Eneida R. Nemecek, (unknown), (unknown), (unknown), (unknown), (unknown), Richard T. Maziarz	6
9	Functional integration of acute myeloid leukemia into the vascular niche 2014 ·Leukemia ·Christopher R. Cogle, (unknown), Gerard J. Madlambayan, Ronald P. Leon, Azzah Al Masri, Helen Clark, (unknown), Jeffrey Tyner, (unknown), Gaofeng Fan, Tibor Kovacsovics, Qianshi Liu, Amy Meacham, (unknown), Robert Hromas, Edward W. Scott, Will Fleming	68
10	Kinase Pathway Dependence in Primary Human Leukemias Determined by Rapid Inhibitor Screening 2012 ·Cancer Research ·Jeffrey Tyner, (unknown), Armand Bankhead, Guang Fan, Luke B. Fletcher, Jade Bryant, Jason Glover, Bill H. Chang, Stephen E. Spurgeon, William H. Fleming, Tibor Kovacsovics, Jason Gotlib, Stephen T. Oh, Michael W. Deininger, C. Michel Zwaan, Monique L. den Boer, Marry M. van den Heuvel‐Eibrink, Thomas O’Hare, Brian Druker, Marc Loriaux	100
11	Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial 2010 ·Haematologica ·T. de Witte, A Hagemeijer, Stefan Suciu, Amine Belhabri, Michel Delforge, Guido Kobbe, (unknown), Harry C. Schouten, Augustin Ferrant, Harald Biersack, Sergio Amadori, Petra Muus, Joop H. Jansen, Eva Hellström‐Lindberg, Tibor Kovacsovics, P. W. Wijermans, GJ Ossenkoppele, Aloïs Gratwohl, J. P. Marie, (unknown)	52
12	Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience 2009 ·Bone Marrow Transplantation ·Cedar Fowler, (unknown), (unknown), Keith Hansen, Lisa Hansen, Keith S. Lanier, Veronica Nelson, Tibor Kovacsovics, José F. Leis, Gary Calandra, Richard T. Maziarz	57
13	Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial 2007 ·Leukemia ·Emmanuelle Tavernier, JM Boiron, Françoise Huguet, K. F. Bradstock, Norbert Vey, Tibor Kovacsovics, André Delannoy, Nathalie Fegueux, Pierre Fenaux, Aspasia Stamatoullas, Olivier Tournilhac, Agnès Buzyn, Oumédaly Reman, C Charrin, Claude Boucheix, J Gäbert, Véronique Lhéritier, Vernant Jp, Hervé Dombret, Xavier Thomas	184
14	Severe Pustular Eruption Associated with Imatinib and Voriconazole in a Patient with Chronic Myeloid Leukemia 2005 ·Dermatology ·(unknown), Emmanuel Laffitte, Nicolas Widmer, Laurent A. Décosterd, Michel A. Duchosal, Tibor Kovacsovics, Renato G. Panizzon	36
15	Systematic screening at diagnosis of −5/del(5)(q31), −7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics 2004 ·Cancer Genetics and Cytogenetics ·(unknown), (unknown), Dominique Mühlematter, V. Parlier, J Gmür, U Hess, Tibor Kovacsovics, Sandrine Meyer‐Monard, André Tichelli, Andreas Tobler, E Jacky, Urs Schanz, Mario Bargetzi, Anne Hagemeijer, Théo de Witte, Guy van Melle, Martine Jotterand	31
16	A Template‐Assembled Synthetic Protein Surface Mimetic of the von Willebrand Factor A1 domain Inhibits Botrocetin‐Induced Platelet Aggregation 2004 ·ChemBioChem ·J Hauert, Jimena Fernández‐Carneado, Olivier Michielin, (unknown), (unknown), M Schapira, Olivier Spertini, Manfred Mutter, Gabriele Tuchscherer, Tibor Kovacsovics	15
17	Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed 2002 ·Journal of Clinical Oncology ·Michael J. Keating, Bruno Cazin, Steven Coutré, Ruemu Birhiray, Tibor Kovacsovics, Wolfgang Langer, Brian Leber, T.S. Maughan, R. Kanti, Geir E. Tjønnfjord, (unknown), M. Itzhaki, Patrice Herait	73
18	Acute Myeloid Leukemia in the Elderly: Results of an Individualized Approach in Two Centres 2000 ·Leukemia & lymphoma ·Vito Spataro, Tibor Kovacsovics, (unknown), S. Pampallona, M Schapira, F. Cavalli	10
19	PP18. Hospital costs of intensive chemotherapy followed by peripheral stem cell reinfusion 1997 ·European Journal of Cancer ·(unknown), Alain Cometta, Tibor Kovacsovics, JB Wasserfallen	1
20	Phosphorylation of the Platelet p47 Phosphoprotein Is Mediated by the Lipid Products of Phosphoinositide 3-Kinase 1995 ·Journal of Biological Chemistry ·Alex Toker, Christilla Bachelot‐Loza, Ching‐Shih Chen, John R. Falck, John H. Hartwig, Lewis C. Cantley, Tibor Kovacsovics	64

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact